ScreenerHero

NTLAIntellia Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · intelliatx.com
12.84USD-3.31%Mkt Cap: 1.80B $P/E: —

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly inters…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap1.80B $
Enterprise Value1.38B $
Revenue (TTM)59.51M $
Gross Profit-222.82M $
Net Income (TTM)-412.69M $
Revenue/Share0.4980 USD
Last Price12.84 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees377
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS45826J1051
Valuation
P/E (Trailing)—
P/E (Forward)-4.78
PEG—
EV/EBITDA-3.33
EV/Revenue23.17
P/S29.29
P/B2.39
EPS (TTM)-3.13
EPS (Forward)-2.60
52W Range
7.95024% of range28.25
52W High28.25 USD
52W Low7.950 USD
Profitability
Gross Margin0.00%
Oper. Margin-1472.26%
EBITDA Margin0.00%
Profit Margin-609.85%
ROE-61.47%
ROA-49.01%
Growth
Revenue Growth-46.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-394.74M $
CapEx (TTM)1.13M $
FCF Margin-419.83%
FCF Yield-13.89%
Net Debt-364.35M $
Net Debt/EBITDA0.88
Balance Sheet
Debt/Equity0.14
Current Ratio6.65
Quick Ratio5.61
Book Value/Sh5.197 USD
Cash/Share3.124 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.3 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)23.94 USD
Upside (mean)+86.5%
Target Range8.000 USD – 61.00 USD
$8.000+86.5% to mean$61.00
# Analysts17
Ownership
Shares Out.140.13M
Float134.42M
Insiders3.86%
Institutions99.91%
Short Interest
Short Ratio10.5d
Short % Float39.57%
Short % Out.31.41%
Shares Short44.01M
Short (prev mo.)49.22M
Technical
SMA 5013.28 (-3.3%)
SMA 20012.42 (+3.4%)
Beta1.79
S&P 52W Chg18.16%
Avg Vol (30d)3.90M
Avg Vol (10d)3.37M
Technical Indicators
RSI (14)55.9
MACD-0.0959
MACD Signal-0.4019
MACD Hist.+0.3060
BB Upper13.02 USD
BB Middle11.51 USD
BB Lower10.01 USD
BB Width26.10%
ATR (14)0.7162 USD
Vol Ratio (20d)0.97x